j) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:101, or

k) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:102, or

l) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:103, or

m) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:104, or

n) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:105, or

o) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:106, or

p) a heavy chain variable domain VH of SEQ ID NO:91 and a light chain variable domain VL of SEQ ID NO:107.

In another aspect, there is provided a tumor-targeted IL-2 variant immunocytokine in combination with an antibody which binds to human PD-L1 for use as a combination therapy in

i) inhibition of tumor growth in a tumor expressing the target of the immunocytokine; and/or

ii) enhancing median and/or overall survival of subjects with a tumor expressing the target of the immunocytokine;

wherein the target is presented on a tumor cell or in a tumor cell environment,

wherein the tumor-targeted IL-2 variant immunocytokine used in the combination therapy is characterized in comprising

o) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:106, or

p) a heavy chain variable domain VH of SEQ ID NO:91 and a light chain variable domain VL of SEQ ID NO:107.

In another aspect, there is provided a carcinoembryonic antigen (CEA)-targeted IL-2 variant immunocytokine in combination with an antibody which binds to human PD-L1 for use as a combination therapy in

i) inhibition of tumor growth in a CEA-expressing tumors; and/or

ii) enhancing median and/or overall survival of subjects with a CEA-expressing tumor,

wherein the CEA-targeted IL-2 variant immunocytokine is to be administered in combination with an antibody which binds to human PD-L1;

wherein the CEA-targeted IL-2 variant immunocytokine used in the combination therapy is characterized in comprising

a) the polypeptide sequences of SEQ ID NO:84, and SEQ ID NO:86 and SEQ ID NO:88, or

b) the polypeptide sequences of SEQ ID NO:108, and SEQ ID NO:109 and SEQ ID NO:110;

and the antibody which binds to human PD-L1 used in the combination therapy is characterized in comprising

m) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:104, or

n) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:105, or

o) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:106, or

p) a heavy chain variable domain VH of SEQ ID NO:91 and a light chain variable domain VL of SEQ ID NO:107.

In another aspect, there is provided a fibroblast activation protein (FAP)-targeted IL-2 variant immunocytokine in combination with an antibody which binds to human PD-L1 for use as a combination therapy in

i) inhibition of tumor growth in a FAP-expressing tumor; and/or

ii) enhancing median and/or overall survival of subjects with a FAP-expressing tumor;

wherein the FAP-targeted IL-2 variant immunocytokine used in the combination therapy is characterized in comprising

a) the polypeptide sequences of SEQ ID NO:79, and SEQ ID NO:80 and SEQ ID NO:81, or

b) the polypeptide sequences of SEQ ID NO:124, and SEQ ID NO:125 and SEQ ID NO:126;

l) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:103, or

m) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:104, or

n) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:105, or

o) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:106, or

p) a heavy chain variable domain VH of SEQ ID NO:91 and a light chain variable domain VL of SEQ ID NO:107.

In another aspect, there is provided a tumor-targeted IL-2 variant immunocytokine in combination with an antibody which binds to human PD-L1 for use as a combination therapy for use in the treatment of a patient having a CEA-expressing tumor or a tumor characterized by expression or overexpression of CEA, having a FAP-expressing tumor or a tumor characterized by expression or overexpression of FAP or having a tumor associated with expression or overexpression of CEA or FAP, and wherein the immunocytokine is administered in combination with an antibody which binds to human PD-L1,

wherein the tumor-targeted IL-2 variant immunocytokine used in the combination therapy is characterized in comprising

o) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:106, or

p) a heavy chain variable domain VH of SEQ ID NO:91 and a light chain variable domain VL of SEQ ID NO:107.

In another aspect, there is provided use of a tumor-targeted IL-2 variant immunocytokine in combination with an antibody which binds to human PD-L1 in the manufacture of a medicament as combination therapy for the

i) inhibition of tumor growth in a tumor expressing the target of the immunocytokine; and/or

ii) enhancing median and/or overall survival of subjects with a tumor expressing the target of the immunocytokine;

wherein the target is presented on a tumor cell or in a tumor cell environment,

wherein the tumor-targeted IL-2 variant immunocytokine used in the combination therapy is characterized in comprising

a) the polypeptide sequences of SEQ ID NO:84, and SEQ ID NO:86 and SEQ ID NO:88, or

b) the polypeptide sequences of SEQ ID NO:108, and SEQ ID NO:109 and SEQ ID NO:110, or

k) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:102, or

l) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:103, or

m) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:104, or

n) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:105, or

o) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:106, or

p) a heavy chain variable domain VH of SEQ ID NO:91 and a light chain variable domain VL of SEQ ID NO:107.

In another aspect, there is provided use of a CEA-targeted IL-2 variant immunocytokine in combination with an antibody which binds to human PD-L1 in the manufacture of a medicament as combination therapy for the

i) inhibition of tumor growth in a CEA-expressing tumors; and/or

ii) enhancing median and/or overall survival of subjects with a CEA-expressing tumor,

wherein the CEA-targeted IL-2 variant immunocytokine is to be administered in combination with an antibody which binds to human PD-L1;

wherein the CEA-targeted IL-2 variant immunocytokine used in the combination therapy is characterized in comprising

l) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:103, or

m) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:104, or

n) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:105, or

o) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:106, or

p) a heavy chain variable domain VH of SEQ ID NO:91 and a light chain variable domain VL of SEQ ID NO:107.

In another aspect, there is provided use of a FAP-targeted IL-2 variant immunocytokine in combination with an antibody which binds to human PD-L1 in the manufacture of a medicament as combination therapy for the

i) inhibition of tumor growth in a FAP-expressing tumor; and/or

ii) enhancing median and/or overall survival of subjects with a FAP-expressing tumor;

wherein the FAP-targeted IL-2 variant immunocytokine used in the combination therapy is characterized in comprising

a) the polypeptide sequences of SEQ ID NO:79, and SEQ ID NO:80 and SEQ ID NO:81, or

b) the polypeptide sequences of SEQ ID NO:124, and SEQ ID NO:125 and SEQ ID NO:126;

and the antibody which binds to human PD-L1 used in the combination therapy is characterized in comprising

j) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:101, or

k) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:102, or

l) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:103, or

m) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:104, or

n) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:105, or

o) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:106, or

p) a heavy chain variable domain VH of SEQ ID NO:91 and a light chain variable domain VL of SEQ ID NO:107.

2. The tumor-targeted IL-2 variant immunocytokine in combination with an antibody which binds to human PD-L1 for use according to claim 1, in the treatment of breast cancer, lung cancer, colon cancer, ovarian cancer, melanoma cancer, bladder cancer, renal cancer, kidney cancer, liver cancer, head and neck cancer, colorectal cancer, melanoma, pancreatic cancer, gastric carcinoma cancer, esophageal cancer, mesothelioma, prostate cancer, leukemia, lymphomas, myelomas.

3. A tumor-targeted IL-2 variant immunocytokine in combination with an antibody which binds to human PD-L1 for use as a combination therapy in

i) inhibition of tumor growth in a tumor expressing the target of the immunocytokine; and/or

ii) enhancing median and/or overall survival of subjects with a tumor expressing the target of the immunocytokine;

wherein the target is presented on a tumor cell or in a tumor cell environment,

wherein the tumor-targeted IL-2 variant immunocytokine used in the combination therapy is characterized in comprising

p) a heavy chain variable domain VH of SEQ ID NO:91 and a light chain variable domain VL of SEQ ID NO:107.

4. A carcinoembryonic antigen (CEA)-targeted IL-2 variant immunocytokine in combination with an antibody which binds to human PD-L1 for use as a combination therapy in

i) inhibition of tumor growth in a CEA-expressing tumors; and/or

ii) enhancing median and/or overall survival of subjects with a CEA-expressing tumor,

wherein the CEA-targeted IL-2 variant immunocytokine is to be administered in combination with an antibody which binds to human PD-L1;

wherein the CEA-targeted IL-2 variant immunocytokine used in the combination therapy is characterized in comprising

a) the polypeptide sequences of SEQ ID NO:84, and SEQ ID NO:86 and SEQ ID NO:88, or

b) the polypeptide sequences of SEQ ID NO:108, and SEQ ID NO:109 and SEQ ID NO:110;

and the antibody which binds to human PD-L1 used in the combination therapy is characterized in comprising

m) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:104, or

n) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:105, or

o) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:106, or

p) a heavy chain variable domain VH of SEQ ID NO:91 and a light chain variable domain VL of SEQ ID NO:107.

5. The CEA-targeted IL-2 variant immunocytokine in combination with an antibody which binds to human PD-L1 for use according to claim 4,

wherein the tumor-targeted IL-2 variant immunocytokine used in the combination therapy is characterized in comprising

the polypeptide sequences of SEQ ID NO:84, SEQ ID NO:86 and SEQ ID NO:88,

and wherein the antibody which binds to human PD-L1 used in the combination therapy is characterized in comprising

a) a heavy chain variable domain VH of SEQ ID NO:89 and a light chain variable domain VL of SEQ ID NO:92.

6. A fibroblast activation protein (FAP)-targeted IL-2 variant immunocytokine in combination with an antibody which binds to human PD-L1 for use as a combination therapy in

i) inhibition of tumor growth in a FAP-expressing tumor; and/or

ii) enhancing median and/or overall survival of subjects with a FAP-expressing tumor;

wherein the FAP-targeted IL-2 variant immunocytokine used in the combination therapy is characterized in comprising

a) the polypeptide sequences of SEQ ID NO:79, and SEQ ID NO:80 and SEQ ID NO:81, or

b) the polypeptide sequences of SEQ ID NO:124, and SEQ ID NO:125 and SEQ ID NO:126;

l) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:103, or

m) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:104, or

n) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:105, or

o) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:106, or

p) a heavy chain variable domain VH of SEQ ID NO:91 and a light chain variable domain VL of SEQ ID NO:107.

7. The FAP-targeted IL-2 variant immunocytokine in combination with an antibody which binds to human PD-L1 for use according to claim 6,

wherein the tumor-targeted IL-2 variant immunocytokine used in the combination therapy is characterized in comprising

the polypeptide sequences of SEQ ID NO:79, SEQ ID NO:80 and SEQ ID NO:81,

and wherein the antibody which binds to human PD-L1 used in the combination therapy is characterized in comprising

a) a heavy chain variable domain VH of SEQ ID NO:89 and a light chain variable domain VL of SEQ ID NO:92.

8. A tumor-targeted IL-2 variant immunocytokine in combination with an antibody which binds to human PD-L1 for use as a combination therapy in the treatment of a patient having a CEA-expressing tumor or a tumor characterized by expression or overexpression of CEA, having a FAP-expressing tumor or a tumor characterized by expression or overexpression of FAP or having a tumor associated with expression or overexpression of CEA or FAP, and wherein the immunocytokine is to be administered in combination with an antibody which binds to human PD-L1,

wherein the tumor-targeted IL-2 variant immunocytokine used in the combination therapy is characterized in comprising

a) the polypeptide sequences of SEQ ID NO:84, and SEQ ID NO:86 and SEQ ID NO:88, or

9. The tumor-targeted IL-2 variant immunocytokine in combination with an antibody which binds to human PD-L1 for use according to any one of claims 1, 2, 3 or 8,

wherein the tumor-targeted IL-2 variant immunocytokine used in the combination therapy is characterized in comprising

the polypeptide sequences of SEQ ID NO:84, SEQ ID NO:86 and SEQ ID NO:88, or

the polypeptide sequences of SEQ ID NO:79, SEQ ID NO:80 and SEQ ID NO:81,

and wherein the antibody which binds to human PD-L1 used in the combination therapy is characterized in comprising

a) a heavy chain variable domain VH of SEQ ID NO:89 and a light chain variable domain VL of SEQ ID NO:92.

10. The tumor-targeted IL-2 variant immunocytokine in combination with an antibody which binds to human PD-L1 for use according to any one of claims 1, 2, 3, 8 or 9, the CEA-targeted IL-2 variant immunocytokine in combination with an antibody which binds to human PD-L1 for use according to claim 4 or 5, or the FAP-targeted IL-2 variant immunocytokine in combination with an antibody which binds to human PD-L1 for use according to claim 6 or 7, characterized in that the antibody component of the immunocytokine and the antibody are of human IgG1 subclass or human IgG4 subclass.

11. The tumor-targeted IL-2 variant immunocytokine in combination with an antibody which binds to human PD-L1 for use according to any one of claims 1, 2, 3, 8, 9, or 10, the CEA-targeted IL-2 variant immunocytokine in combination with an antibody which binds to human PD-L1 for use according to any one of claims 4, 5 or

10, or the FAP-targeted IL-2 variant immunocytokine in combination with an antibody which binds to human PD-L1 for use according to any one of claims 6, 7 or 10, characterized in that said antibodies have reduced or minimal effector function.

12. The tumor-targeted IL-2 variant immunocytokine in combination with an antibody which binds to human PD-L1 for use according to claim 11, the CEA-targeted IL-2 variant immunocytokine in combination with an antibody which binds to human PD-L1 for use according to claim 11, or the FAP-targeted IL-2 variant immunocytokine in combination with an antibody which binds to human PD-L1 for use according to claim 11, wherein the minimal effector function results from an effectorless Fc mutation.

13. The tumor-targeted IL-2 variant immunocytokine in combination with an antibody which binds to human PD-L1 for use according to claim 12, the CEA-targeted IL-2 variant immunocytokine in combination with an antibody which binds to human PD-L1 for use according to claim 12, or the FAP-targeted IL-2 variant immunocytokine in combination with an antibody which binds to human PD-L1 for use according to claim 12, wherein the effectorless Fc mutation is L234A/L235A or L234A/L235A/P329G or N297A or D265A/N297A.

14. Use of a tumor-targeted IL-2 variant immunocytokine in combination with an antibody which binds to human PD-L1 in the manufacture of a medicament as a combination therapy in the treatment of cancer,

wherein the tumor-targeted IL-2 variant immunocytokine used in the combination therapy is characterized in comprising

a) the polypeptide sequences of SEQ ID NO:84, and SEQ ID NO:86 and SEQ ID NO:88, or

b) the polypeptide sequences of SEQ ID NO:108, and SEQ ID NO:109 and SEQ ID NO:110, or

j) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:101, or

k) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:102, or

l) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:103, or

m) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:104, or

n) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:105, or

o) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:106, or

p) a heavy chain variable domain VH of SEQ ID NO:91 and a light chain variable domain VL of SEQ ID NO:107.

15. Use of a tumor-targeted IL-2 variant immunocytokine in combination with an antibody which binds to human PD-L1 in the manufacture of a medicament as combination therapy for the

i) inhibition of tumor growth in a tumor expressing the target of the immunocytokine; and/or

ii) enhancing median and/or overall survival of subjects with a tumor expressing the target of the immunocytokine;

wherein the target is presented on a tumor cell or in a tumor cell environment,

wherein the tumor-targeted IL-2 variant immunocytokine used in the combination therapy is characterized in comprising

16. Use of a CEA-targeted IL-2 variant immunocytokine in combination with an antibody which binds to human PD-L1 in the manufacture of a medicament as combination therapy for the

i) inhibition of tumor growth in a CEA-expressing tumors; and/or

ii) enhancing median and/or overall survival of subjects with a CEA-expressing tumor,

wherein the CEA-targeted IL-2 variant immunocytokine is to be administered in combination with an antibody which binds to human PD-L1;

wherein the CEA-targeted IL-2 variant immunocytokine used in the combination therapy is characterized in comprising

a) the polypeptide sequences of SEQ ID NO:84, and SEQ ID NO:86 and SEQ ID NO:88, or

b) the polypeptide sequences of SEQ ID NO:108, and SEQ ID NO:109 and SEQ ID NO:110;

and the antibody which binds to human PD-L1 used in the combination therapy is characterized in comprising

a) a heavy chain variable domain VH of SEQ ID NO:89 and a light chain variable domain VL of SEQ ID NO:92, or

b) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:93, or

p) a heavy chain variable domain VH of SEQ ID NO:91 and a light chain variable domain VL of SEQ ID NO:107.

17. Use of a FAP-targeted IL-2 variant immunocytokine in combination with an antibody which binds to human PD-L1 in the manufacture of a medicament as combination therapy for the

i) inhibition of tumor growth in a FAP-expressing tumor; and/or

ii) enhancing median and/or overall survival of subjects with a FAP-expressing tumor;

wherein the FAP-targeted IL-2 variant immunocytokine used in the combination therapy is characterized in comprising

a) the polypeptide sequences of SEQ ID NO:79, and SEQ ID NO:80 and SEQ ID NO:81, or

b) the polypeptide sequences of SEQ ID NO:124, and SEQ ID NO:125 and SEQ ID NO:126;

and the antibody which binds to human PD-L1 used in the combination therapy is characterized in comprising

a) a heavy chain variable domain VH of SEQ ID NO:89 and a light chain variable domain VL of SEQ ID NO:92, or

b) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:93, or

p) a heavy chain variable domain VH of SEQ ID NO:91 and a light chain variable domain VL of SEQ ID NO:107.

17. Use of a tumor-targeted IL-2 variant immunocytokine in the manufacture of a medicament for the treatment of a patient having a CEA-expressing tumor or a tumor characterized by expression or overexpression of CEA, having a FAP-expressing tumor or a tumor characterized by expression or overexpression of FAP or having a tumor associated with expression or overexpression of CEA or FAP, and wherein the immunocytokine is to be administered in combination with an antibody which binds to human PD-L1,

wherein the tumor-targeted IL-2 variant immunocytokine used in the combination therapy is characterized in comprising

a) the polypeptide sequences of SEQ ID NO:84, and SEQ ID NO:86 and SEQ ID NO:88, or

b) the polypeptide sequences of SEQ ID NO:108, and SEQ ID NO:109 and SEQ ID NO:110, or

c) the polypeptide sequences of SEQ ID NO:79, and SEQ ID NO:80 and SEQ ID NO:81, or